A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Trial Profile

A Phase II trial to assess the efficacy and safety of pasireotide s.c. alone or in combination with cabergoline in patients with Cushing's disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Pasireotide (Primary) ; Cabergoline
  • Indications Pituitary ACTH hypersecretion
  • Focus Therapeutic Use
  • Acronyms CAPACITY
  • Sponsors Novartis
  • Most Recent Events

    • 11 Nov 2017 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.
    • 11 Nov 2017 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2019.
    • 04 Apr 2017 Results assessing safety and efficacy of pasireotide monotherapy or in combination with cabergoline in patients with Cushing's disease, presented at The 99th Annual Meeting of the Endocrine Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top